A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms PrefHer
- Sponsors Roche
- 11 Oct 2016 Results assessing efficacy presented at the 41st European Society for Medical Oncology Congress (2016).
- 13 Mar 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
- 21 Mar 2014 Healthcare professional results presented at the 9th European Breast Cancer Conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History